| 1 | LLY | Eli Lilly and Company | $1.08T | 42.9 | 0.5% |
| 2 | JNJ | Johnson & Johnson | $613.02B | 29.5 | 2.1% |
| 3 | ABBV | AbbVie Inc | $447.62B | 123.6 | 2.8% |
| 4 | UNH | UnitedHealth Group Incorporated | $388.59B | 32.3 | 2.1% |
| 5 | MRK | Merck & Company Inc | $317.77B | 36.2 | 2.6% |
| 6 | NVS | Novartis AG ADR | $296.54B | 22.3 | 3.0% |
| 7 | AZN | AstraZeneca PLC | $292.20B | 28.4 | 1.7% |
| 8 | NVO | Novo Nordisk A/S | $212.80B | 11.6 | 3.8% |
| 9 | AMGN | Amgen Inc | $193.39B | 24.9 | 2.7% |
| 10 | TMO | Thermo Fisher Scientific Inc | $190.65B | 28.2 | 0.4% |
| 11 | ABT | Abbott Laboratories | $163.94B | 26.4 | 2.6% |
| 12 | GILD | Gilead Sciences Inc | $158.77B | 17.4 | 2.6% |
| 13 | ISRG | Intuitive Surgical Inc | $143.33B | 49.2 | — |
| 14 | DHR | Danaher Corporation | $138.86B | 38.0 | 0.7% |
| 15 | PFE | Pfizer Inc | $138.44B | 18.5 | 7.3% |
| 16 | CVS | CVS Health Corp | $133.13B | 45.6 | 2.5% |
| 17 | SYK | Stryker Corporation | $127.55B | 38.5 | 1.1% |
| 18 | VRTX | Vertex Pharmaceuticals Inc | $124.70B | 29.2 | — |
| 19 | BMY | Bristol-Myers Squibb Company | $117.46B | 16.1 | 4.5% |
| 20 | GSK | GlaxoSmithKline PLC ADR | $105.17B | 14.0 | 3.4% |
| 21 | MDT | Medtronic PLC | $103.66B | 21.7 | 3.6% |
| 22 | SNY | Sanofi ADR | $102.81B | 19.1 | 0.0% |
| 23 | MCK | McKesson Corporation | $89.39B | 19.9 | 0.4% |
| 24 | HCA | HCA Healthcare, Inc. | $86.89B | 13.5 | 0.8% |
| 25 | ELV | Elevance Health Inc | $85.82B | 16.8 | 1.8% |
| 26 | CI | Cigna Corp | $74.81B | 12.0 | 2.2% |
| 27 | MDLN | Medline Inc. Class A Common Stock | $69.26B | 34.1 | — |
| 28 | REGN | Regeneron Pharmaceuticals Inc | $66.35B | 15.5 | 0.6% |
| 29 | BSX | Boston Scientific Corp | $65.74B | 18.5 | — |
| 30 | CAH | Cardinal Health Inc | $55.72B | 36.4 | 0.9% |
| 31 | COR | Cencora Inc. | $55.67B | 21.9 | 0.8% |
| 32 | ARGX | argenx NV ADR | $55.44B | 39.4 | — |
| 33 | EW | Edwards Lifesciences Corp | $52.27B | 48.6 | — |
| 34 | TAK | Takeda Pharmaceutical Co Ltd ADR | $50.27B | — | 4.2% |
| 35 | HUM | Humana Inc | $46.08B | 41.0 | 0.9% |
| 36 | IDXX | IDEXX Laboratories Inc | $43.50B | 40.6 | — |
| 37 | BDX | Becton Dickinson and Company | $42.96B | 27.3 | 2.8% |
| 38 | HLN | Haleon plc | $40.72B | 18.9 | 2.1% |
| 39 | ALNY | Alnylam Pharmaceuticals Inc | $38.90B | 73.0 | — |
| 40 | RVMD | Revolution Medicines Inc | $38.71B | — | — |
| 41 | TEVA | Teva Pharma Industries Ltd ADR | $38.67B | 24.8 | — |
| 42 | A | Agilent Technologies Inc | $38.41B | 27.3 | 0.7% |
| 43 | NTRA | Natera Inc | $37.51B | — | — |
| 44 | WAT | Waters Corporation | $36.76B | 47.6 | — |
| 45 | ALC | Alcon AG | $33.07B | 40.6 | 0.5% |
| 46 | CNC | Centene Corp | $32.46B | — | — |
| 47 | RPRX | Royalty Pharma Plc | $32.38B | 29.6 | 1.6% |
| 48 | IQV | IQVIA Holdings Inc | $31.90B | 23.7 | — |
| 49 | ZTS | Zoetis Inc | $31.90B | 12.5 | 2.6% |
| 50 | BIIB | Biogen Inc | $31.89B | 23.3 | — |
| 51 | GEHC | GE HealthCare Technologies Inc. | $29.91B | 15.8 | 0.2% |
| 52 | RMD | ResMed Inc | $29.05B | 19.3 | 1.2% |
| 53 | ONC | BeiGene, Ltd. | $29.04B | 63.3 | — |
| 54 | VEEV | Veeva Systems Inc Class A | $27.84B | 30.4 | — |
| 55 | DXCM | DexCom Inc | $27.07B | 30.1 | — |
| 56 | ILMN | Illumina Inc | $26.71B | 32.0 | — |
| 57 | MRNA | Moderna Inc | $26.69B | — | — |
| 58 | PHG | Koninklijke Philips NV ADR | $26.34B | 23.8 | 3.7% |
| 59 | MTD | Mettler-Toledo International Inc | $25.54B | 29.7 | — |
| 60 | WST | West Pharmaceutical Services Inc | $24.79B | 47.0 | 0.3% |
| 61 | ROIV | Roivant Sciences Ltd | $24.51B | — | — |
| 62 | DGX | Quest Diagnostics Incorporated | $23.23B | 23.2 | 1.6% |
| 63 | BNTX | BioNTech SE | $23.07B | — | — |
| 64 | UTHR | United Therapeutics Corporation | $23.03B | 20.1 | — |
| 65 | INCY | Incyte Corporation | $22.73B | 16.1 | — |
| 66 | INSM | Insmed Inc | $22.41B | — | — |
| 67 | LH | Laboratory Corporation of America Holdings | $22.26B | 24.1 | 1.1% |
| 68 | STE | STERIS plc | $21.02B | 27.2 | 1.2% |
| 69 | GH | Guardant Health Inc | $19.79B | — | — |
| 70 | VTRS | Viatris Inc | $19.02B | — | 3.0% |
| 71 | ZBH | Zimmer Biomet Holdings Inc | $18.01B | 24.1 | 1.1% |
| 72 | ASND | Ascendis Pharma AS | $17.10B | 30.3 | — |
| 73 | NBIX | Neurocrine Biosciences Inc | $16.94B | 25.9 | — |
| 74 | THC | Tenet Healthcare Corporation | $16.28B | 9.8 | — |
| 75 | GMAB | Genmab AS | $16.04B | 19.8 | — |
| 76 | MEDP | Medpace Holdings Inc | $15.05B | 33.2 | — |
| 77 | JAZZ | Jazz Pharmaceuticals PLC | $14.45B | 1,916.8 | — |
| 78 | DVA | DaVita HealthCare Partners Inc | $13.93B | 20.9 | — |
| 79 | COO | The Cooper Companies, Inc | $13.85B | 60.2 | — |
| 80 | SOLV | Solventum Corp. | $13.77B | 9.7 | — |
| 81 | EXEL | Exelixis Inc | $13.77B | 18.1 | — |
| 82 | BBIO | BridgeBio Pharma Inc | $13.76B | — | — |
| 83 | BTSG | BrightSpring Health Services, Inc. Common Stock | $13.54B | 89.6 | — |
| 84 | IONS | Ionis Pharmaceuticals Inc | $13.42B | — | — |
| 85 | ICLR | ICON PLC | $13.01B | 74.5 | — |
| 86 | RDY | Dr. Reddy’s Laboratories Ltd ADR | $12.81B | 28.5 | 0.5% |
| 87 | ALGN | Align Technology Inc | $12.78B | 30.0 | — |
| 88 | SNN | Smith & Nephew SNATS Inc | $12.69B | 21.0 | 2.6% |
| 89 | RVTY | Revvity Inc. | $12.61B | 54.3 | 0.3% |
| 90 | FMS | Fresenius Medical Care Corporation | $12.48B | 12.5 | 3.8% |
| 91 | PEN | Penumbra Inc | $12.45B | 73.0 | — |
| 92 | AXSM | Axsome Therapeutics Inc | $12.44B | — | — |
| 93 | ELAN | Elanco Animal Health | $12.27B | — | — |
| 94 | MOH | Molina Healthcare Inc | $11.97B | 61.8 | — |
| 95 | MDGL | Madrigal Pharmaceuticals Inc | $11.82B | — | — |
| 96 | GMED | Globus Medical | $11.71B | 20.2 | — |
| 97 | BMRN | Biomarin Pharmaceutical Inc | $11.40B | 42.5 | — |
| 98 | BAX | Baxter International Inc | $11.38B | — | 1.7% |
| 99 | CYTK | Cytokinetics Inc | $11.16B | — | — |
| 100 | ARWR | Arrowhead Pharmaceuticals Inc | $11.11B | — | — |